These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 34644535)

  • 1. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
    Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
    Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice.
    Pavan MF; Bok M; Betanzos San Juan R; Malito JP; Marcoppido GA; Franco DR; Militelo DA; Schammas JM; Bari SE; Stone W; López K; Porier DL; Muller JA; Auguste AJ; Yuan L; Wigdorovitz A; Parreño VG; Ibañez LI
    Viruses; 2024 Jan; 16(2):. PubMed ID: 38399961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
    Hanke L; Das H; Sheward DJ; Perez Vidakovics L; Urgard E; Moliner-Morro A; Kim C; Karl V; Pankow A; Smith NL; Porebski B; Fernandez-Capetillo O; Sezgin E; Pedersen GK; Coquet JM; Hällberg BM; Murrell B; McInerney GM
    Nat Commun; 2022 Jan; 13(1):155. PubMed ID: 35013189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
    Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
    Front Immunol; 2022; 13():863831. PubMed ID: 35547740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.
    Valenzuela Nieto G; Jara R; Watterson D; Modhiran N; Amarilla AA; Himelreichs J; Khromykh AA; Salinas-Rebolledo C; Pinto T; Cheuquemilla Y; Margolles Y; López González Del Rey N; Miranda-Chacon Z; Cuevas A; Berking A; Deride C; González-Moraga S; Mancilla H; Maturana D; Langer A; Toledo JP; Müller A; Uberti B; Krall P; Ehrenfeld P; Blesa J; Chana-Cuevas P; Rehren G; Schwefel D; Fernandez LÁ; Rojas-Fernandez A
    Sci Rep; 2021 Feb; 11(1):3318. PubMed ID: 33558635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies.
    Güttler T; Aksu M; Dickmanns A; Stegmann KM; Gregor K; Rees R; Taxer W; Rymarenko O; Schünemann J; Dienemann C; Gunkel P; Mussil B; Krull J; Teichmann U; Groß U; Cordes VC; Dobbelstein M; Görlich D
    EMBO J; 2021 Oct; 40(19):e107985. PubMed ID: 34302370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.
    Sluchanko NN; Shcheblyakov DV; Varfolomeeva LA; Favorskaya IA; Dolzhikova IV; Korobkova AI; Alekseeva IA; Esmagambetov IB; Derkaev AA; Prokofiev VV; Zorkov ID; Logunov DY; Gintsburg AL; Popov VO; Boyko KM
    Biochemistry (Mosc); 2024 Jul; 89(7):1260-1272. PubMed ID: 39218023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.
    Lim SA; Gramespacher JA; Pance K; Rettko NJ; Solomon P; Jin J; Lui I; Elledge SK; Liu J; Bracken CJ; Simmons G; Zhou XX; Leung KK; Wells JA
    MAbs; 2021; 13(1):1893426. PubMed ID: 33666135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
    Wheatley AK; Pymm P; Esterbauer R; Dietrich MH; Lee WS; Drew D; Kelly HG; Chan LJ; Mordant FL; Black KA; Adair A; Tan HX; Juno JA; Wragg KM; Amarasena T; Lopez E; Selva KJ; Haycroft ER; Cooney JP; Venugopal H; Tan LL; O Neill MT; Allison CC; Cromer D; Davenport MP; Bowen RA; Chung AW; Pellegrini M; Liddament MT; Glukhova A; Subbarao K; Kent SJ; Tham WH
    Cell Rep; 2021 Oct; 37(2):109822. PubMed ID: 34610292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
    Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
    Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
    Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
    Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.
    Fu D; Zhang G; Wang Y; Zhang Z; Hu H; Shen S; Wu J; Li B; Li X; Fang Y; Liu J; Wang Q; Zhou Y; Wang W; Li Y; Lu Z; Wang X; Nie C; Tian Y; Chen D; Wang Y; Zhou X; Wang Q; Yu F; Zhang C; Deng C; Zhou L; Guan G; Shao N; Lou Z; Deng F; Zhang H; Chen X; Wang M; Liu L; Rao Z; Guo Y
    PLoS Biol; 2021 May; 19(5):e3001209. PubMed ID: 33961621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.
    De Gasparo R; Pedotti M; Simonelli L; Nickl P; Muecksch F; Cassaniti I; Percivalle E; Lorenzi JCC; Mazzola F; Magrì D; Michalcikova T; Haviernik J; Honig V; Mrazkova B; Polakova N; Fortova A; Tureckova J; Iatsiuk V; Di Girolamo S; Palus M; Zudova D; Bednar P; Bukova I; Bianchini F; Mehn D; Nencka R; Strakova P; Pavlis O; Rozman J; Gioria S; Sammartino JC; Giardina F; Gaiarsa S; Pan-Hammarström Q; Barnes CO; Bjorkman PJ; Calzolai L; Piralla A; Baldanti F; Nussenzweig MC; Bieniasz PD; Hatziioannou T; Prochazka J; Sedlacek R; Robbiani DF; Ruzek D; Varani L
    Nature; 2021 May; 593(7859):424-428. PubMed ID: 33767445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
    Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X
    Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes.
    Li M; Zhao C; Shi J; Wang X; Liu Y; Zhao X; Cai G; Chu H; Wang P
    Emerg Microbes Infect; 2024 Dec; 13(1):2404166. PubMed ID: 39258934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.
    Xiang Y; Nambulli S; Xiao Z; Liu H; Sang Z; Duprex WP; Schneidman-Duhovny D; Zhang C; Shi Y
    Science; 2020 Dec; 370(6523):1479-1484. PubMed ID: 33154108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22).
    Wu X; Wang Y; Cheng L; Ni F; Zhu L; Ma S; Huang B; Ji M; Hu H; Li Y; Xu S; Shi H; Zhang D; Liu L; Nawaz W; Hu Q; Ye S; Liu Y; Wu Z
    Front Immunol; 2022; 13():865401. PubMed ID: 35371009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.